Aion Therapeutic Stock Performance
| ANTCF Stock | USD 0.03 0.02 185.71% |
Aion Therapeutic holds a performance score of 15 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -17.56, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Aion Therapeutic are expected to decrease by larger amounts. On the other hand, during market turmoil, Aion Therapeutic is expected to outperform it. Use Aion Therapeutic total risk alpha and the relationship between the skewness and price action indicator , to analyze future returns on Aion Therapeutic.
Risk-Adjusted Performance
15 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Aion Therapeutic are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain fundamental indicators, Aion Therapeutic reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 239.8 K | |
| Free Cash Flow | -1.3 M |
Aion |
Aion Therapeutic Relative Risk vs. Return Landscape
If you would invest 0.68 in Aion Therapeutic on September 3, 2024 and sell it today you would earn a total of 2.32 from holding Aion Therapeutic or generate 341.18% return on investment over 90 days. Aion Therapeutic is currently producing 12.1058% returns and takes up 62.4854% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Aion, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Aion Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aion Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Aion Therapeutic, and traders can use it to determine the average amount a Aion Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1937
| Best Portfolio | Best Equity | ANTCF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 62.49 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.19 actual daily | 15 85% of assets perform better |
Based on monthly moving average Aion Therapeutic is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aion Therapeutic by adding it to a well-diversified portfolio.
Aion Therapeutic Fundamentals Growth
Aion Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Aion Therapeutic, and Aion Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aion Pink Sheet performance.
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 147.3 M | |||
| Price To Book | 5.77 X | |||
| EBITDA | (3.68 M) | |||
| Cash And Equivalents | 1.85 K | |||
| Total Debt | 643.8 K | |||
| Debt To Equity | 0.14 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.35 M) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 150.14 K | |||
About Aion Therapeutic Performance
By analyzing Aion Therapeutic's fundamental ratios, stakeholders can gain valuable insights into Aion Therapeutic's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aion Therapeutic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aion Therapeutic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Aion Therapeutic Inc., a pharmaceutical company, offer medical cannabis products in Canada. Aion Therapeutic Inc. was incorporated in 2011 and is headquartered in Toronto, Canada. Aion Therapeutic is traded on OTC Exchange in the United States.Things to note about Aion Therapeutic performance evaluation
Checking the ongoing alerts about Aion Therapeutic for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Aion Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aion Therapeutic is way too risky over 90 days horizon | |
| Aion Therapeutic has some characteristics of a very speculative penny stock | |
| Aion Therapeutic appears to be risky and price may revert if volatility continues | |
| Aion Therapeutic has high likelihood to experience some financial distress in the next 2 years | |
| Aion Therapeutic has accumulated 643.8 K in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Aion Therapeutic has a current ratio of 0.15, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Aion Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Aion Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aion Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aion to invest in growth at high rates of return. When we think about Aion Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.82 M) with loss before overhead, payroll, taxes, and interest of (1.5 K). | |
| Aion Therapeutic has accumulated about 1.85 K in cash with (1.35 M) of positive cash flow from operations. | |
| Roughly 18.0% of Aion Therapeutic shares are held by company insiders |
- Analyzing Aion Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aion Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Aion Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aion Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aion Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aion Therapeutic's pink sheet. These opinions can provide insight into Aion Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aion Pink Sheet analysis
When running Aion Therapeutic's price analysis, check to measure Aion Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aion Therapeutic is operating at the current time. Most of Aion Therapeutic's value examination focuses on studying past and present price action to predict the probability of Aion Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aion Therapeutic's price. Additionally, you may evaluate how the addition of Aion Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |